Immunotherapy for Lung Cancer
10.16476/j.pibb.2025.0038
- VernacularTitle:肺癌免疫治疗
- Author:
Pei-Yang LI
1
;
Feng-Qi LI
2
;
Xiao-Jun HOU
3
;
Xue-Ren LI
4
;
Xin MU
4
;
Hui-Min LIU
4
;
Shou-Chun PENG
1
Author Information
1. Medical School of Tianjin University, Tianjin 300072, China
2. School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
3. Department of Reproductive Medicine, Tianjin First Central Hospital, Tianjin 300192, China
4. Department of Respiratory Medicine, Jinnan Hospital of Tianjin University (Tianjin Jinnan Hospital), Tianjin 300350, China
- Publication Type:Journal Article
- Keywords:
lung cancer;
immunotherapy;
immune checkpoint inhibitors;
tumor-specific antigen-targeted therapy;
adoptive cell therapy;
cancer vaccines;
oncolytic viruses
- From:
Progress in Biochemistry and Biophysics
2025;52(8):1998-2017
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common malignant tumor worldwide, ranking first in both incidence and mortality rates. According to the latest statistics from the International Agency for Research on Cancer (IARC), approximately 2.5 million new cases and around 1.8 million deaths from lung cancer occurred in 2022, placing a tremendous burden on global healthcare systems. The high mortality rate of lung cancer is closely linked to its subtle early symptoms, which often lead to diagnosis at advanced stages. This not only complicates treatment but also results in substantial economic losses. Current treatment options for lung cancer include surgery, radiotherapy, chemotherapy, targeted drug therapy, and immunotherapy. Among these, immunotherapy has emerged as the most groundbreaking advancement in recent years, owing to its unique antitumor mechanisms and impressive clinical benefits. Unlike traditional therapies such as radiotherapy and chemotherapy, immunotherapy activates or enhances the patient’s immune system to recognize and eliminate tumor cells. It offers advantages such as more durable therapeutic effects and relatively fewer toxic side effects. The main approaches to lung cancer immunotherapy include immune checkpoint inhibitors, tumor-specific antigen-targeted therapies, adoptive cell therapies, cancer vaccines, and oncolytic virus therapies. Among these, immune checkpoint inhibitors and tumor-specific antigen-targeted therapies have received approval from the U.S. Food and Drug Administration (FDA) for clinical use in lung cancer, significantly improving outcomes for patients with advanced non-small cell lung cancer. Although other immunotherapy strategies are still in clinical trials, they show great potential in improving treatment precision and efficacy. This article systematically reviews the latest research progress in lung cancer immunotherapy, including the development of novel immune checkpoint molecules, optimization of treatment strategies, identification of predictive biomarkers, and findings from recent clinical trials. It also discusses the current challenges in the field and outlines future directions, such as the development of next-generation immunotherapeutic agents, exploration of more effective combination regimens, and the establishment of precise efficacy prediction systems. The aim is to provide a valuable reference for the continued advancement of lung cancer immunotherapy.
